Drugs / Albumin paclitaxel/neutrophil drug
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06496724 | Jun 2024 → Jun 2025 overdue | breast cancer | JIANG LONGWEI | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Albumin paclitaxel/neutrophil drug | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06496724 ↗ |
| Route | Intravenous | “Then the drug will be infused intravenously into patients.” NCT06496724 ↗ |